.png)
.png)
Latest news from BIA
£30 million Biomedical Catalyst opens for applications following successful BIA campaign
From today, innovative biotech companies will be able to apply for access to a share of £30 million in grant funding through a relaunched Biomedical Catalyst.
Government announces funding for scale up of COVID-19 vaccine with additional investment to support upskilling in Cell and Gene Therapy and Vaccine manufacturing
Today the Department of Business, Energy and Industrial Strategy has awarded £100 million to fund a Cell and Gene Therapy Catapult Manufacturing Innovation Centre to accelerate production of a COVID-19 vaccine in the UK.
BIA welcomes Global AMR Action Fund to tackle antimicrobial resistance
Steve Bates OBE, Chief Executive of the BIA said: “Antimicrobial resistance (AMR) is one of the key global challenges of our times. Despite being a global health (and BIA) policy focus for years, no market solution has yet delivered the incentives needed to make novel antibiotic development an attractive investment prospect.
BIA welcomes new deal between Vertex and NHS England
Steve Bates OBE, Chief Executive of the BIA said: “It’s fantastic to see the NHS and Vertex strike a lightning quick deal to enable NHS cystic fibrosis patients to access this important breakthrough therapy.
Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
• CRISPR-based screening technology platform to address critical gaps in target ID and validation • Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight
Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics
TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform
CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture
CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) announced today their collaboration in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies.
Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®
Second API Supplier for BARHEMSYS® Receives FDA Approval This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Government changes UK SPC waiver following BIA intervention
The BIA has successfully argued for a significant change in approach to the UK’s Supplementary Protection Certificate (SPC) manufacturing waiver. The BIA’s engagement with the Government was led by Andrew Hutchinson, Partner at Simmons and Simmons and member of the BIA’s Intellectual Property Advisory Committee (IPAC). Here he provides an update following the Government’s response to the consultation and publication of draft legislation.
Guest Blog|COVID19: Where there’s a will there’s a way
The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face. At Exploristics, we have been involved in multiple projects relating to the development of new treatments and diagnostics.
CEO Update|Monday 27 July
Progress towards the development of COVID-19 vaccines continues as the Cell and Gene Therapy Catapult has stepped up to increase the UK’s capacity and capability to manufacture successful COVID-19 vaccines.
CEO Update|Monday 20 July
Big steps forward in the development of vaccines against COVID-19 for the UK today that the BIA and its members have been working towards for months. In a series of announcements the Government has unveiled a number of deals to secure access to 90 million doses of COVID-19 vaccine candidates. To facilitate the development of candidates, a new NHS registry has been set up to help make recruitment into clinical trials run smoothly.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
